| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.8M | — | — |
| R&D Expense | $13.1M | — | -3.5% |
| SG&A Expense | $6.8M | — | -20.5% |
| Operating Income | -$9.1M | — | +59.0% |
| Net Income | -$18.4M | — | +10.3% |
| EPS (Basic) | -$0.75 | — | +66.1% |
| EPS (Diluted) | -$0.75 | — | +66.1% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $99.4M | -10.3% | +28.7% |
| Short-term Investments | $1.8M | -61.9% | — |
| Accounts Receivable | $4.0M | — | — |
| Current Assets | $108.7M | -8.5% | +32.4% |
| Total Assets | $143.9M | -6.8% | +15.7% |
| Current Liabilities | $7.8M | -13.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$11.9M | — | +37.3% |
| Investing Cash Flow | -$114K | — | +63.7% |
| Financing Cash Flow | $745K | — | -93.0% |
| -37.4% |
| Total Liabilities | $67.8M | +9.0% | -9.7% |
| Stockholders' Equity | $76.1M | -17.5% | +54.2% |